Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvo's Pennsaid “Approvable” For Osteoarthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to meet with FDA in early 2007 to discuss the topical non-steroidal anti-inflammatory treatment.
Advertisement

Related Content

Nuvo/Mallinckrodt’s Pennsaid Setback Starts Clock On Generic Launch
Nuvo/Mallinckrodt’s Pennsaid Setback Starts Clock On Generic Launch
Nuvo/Galderma Face More Manufacturing Woes Over Topical Anesthetic
Nuvo’s Pennsaid Resubmission Delayed Again
Nuvo’s Pennsaid Resubmission Delayed Again
Nuvo’s Pennsaid May Need Additional Data Before Approval
Nuvo’s Pennsaid May Need Additional Data Before Approval
Paladin Assumes All Canadian Marketing Of Nuvo’s Pennsaid
Pennsaid Amended NDA Has Mid-December User Fee Date
Pennsaid Amended NDA Has Mid-December User Fee Date

Topics

Advertisement
UsernamePublicRestriction

Register

PS063615

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel